As a major international publisher of academic and research journals, Oxford Journals publishes and develops titles in partnership with the world's most prestigious learned societies. Our goal is to bring high quality research to the widest possible audience.

The Johns Hopkins School of Medicine's Brain Science Institute (BSi) brings together both basic and clinical neuroscientists from across the Johns Hopkins campuses. The BSi represents one of the largest and most diverse groups in the University. The goals of our research is to foster new programs in basic neuroscience discovery, initiate a translational research program that will develop new treatments for brain-based diseases and encourage collaboration, interdisciplinary teams, and new thinking that will have a global influence on research and treatment of the nervous system.

The Johns Hopkins Medicine Brain Science Institute's (BSi) mission is to solve fundamental questions about brain development and function and to use these insights to understand the mechanisms of brain disease

News from Johns Hopkins Departments of Neurology and Neurosurgery

Reprint from ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, Vol. 70. January 1989 - Spasticity: Quantitative Measurements as a Basis for Assessing Effectiveness of Therapeutic Intervention

Reseach Mission is to advance neuromuscular functional assessment using objective measurements of muscle tone, strength, and gait. Goal: To apply innovative techniques to facilitate improved treatment strategies and research evaluation.Our work includes measurement of neuromuscular and musculoskeletal function and dysfunction, with emphasis on quantification of the interrelationships of muscle tone, strength, and gait related to medical diagnosis such as: *Cerebral Palsy*Parkinson's Disease*Spinal Cord Injury *Primary Progressive Multiple Sclerosis*Normal Pressure Hydrocephalus*Obesity*Normal aging *Stroke*Transverse Myelitis*Traumatic Brain Injury

Completed study comparing the blood drug levels of two prescribed medications, Immediate-release omeprazole 40 mg powder and delayed-release omeprazole 40 mg capsule to determine which drug is better absorbed in patients with a slow stomach emptying (gastroparesis). Delayed-release omeprazole has a protective coating to prevent the drug omeprazole from being neutralized by stomach acid. Immediate-release omeprazole has sodium bicarbonate (antacid) which neutralizes the stomach acid, eliminating the need for a protective coating. Immediate-release omeprazole suspension may have a more rapid pharmacokinetic profile and greater overall drug absorption in gastroparesis.

Future planned study with the objective of evaluating the relative merits, safety and effectiveness of the tailored TIF2 procedure in treating GERD patients who have persistent GERD symptoms despite PPI therapy.The secondary objective of the study is to evaluate the effectiveness of the tailored TIF procedure in restoring the antireflux barrier and eliminating gastroesophageal reflux.

Completed study on Motilin, a peptide, whose action is controlled by motilin receptors located in the gut. Action of Motilin at motilin receptors increases the gastric emptying rate (rate of emptying of food and fluid from the stomach). Compounds which stimulate motilin receptors therefore provide a potential approach to the treatment of a range of clinical conditions where delayed gastric emptying may contribute to symptoms, such as enteral feeding ntolerance (post-operative or intensive care patients), gastroparesis, diabetic gastroparesis, and functional dyspepsia. This study is the First Time In Human study for the motilin receptor agonist, GSK962040.

Planned future study investigating the protein composition of nutrition may affect the rate of gastric emptying and gastric pysiology. This is espesially important in children with neurologic impariment, who commonly rely on tube feedings, have feeding proThe intent is to find out whether 4 different protein sources affect the rate of gastric emptying and electrofysiology in this group of children

Study designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.

Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis

Compare the percent of subjects with moderate/severe esophagitis who achieve complete endoscopic resolution after 8 weeks of treatment morning vs. bedtime

Study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.

Study Question: In premature infants with apnea and/or bradycardia attributed to gastroesophageal reflux disease (GERD), does treatment with medications (acid blockers and motility agents), compared to placebo, reduce the frequency of apnea and bradycardia?"

Planned study is to determine if a weekly dose of Progesterone (17OHP) given to women with preterm rupture of the membranes will: 1.increase the probability of continuing the pregnancy until a favorable gestational age. 2.increase the interval between randomization and delivery.3.decrease neonatal morbidity.

Hospital de Clinicas de Porto Alegre completed study evaluated the efficacy and safety of a phytotherapeutic laxative tea, composed by Pimpinella anisum, Foeniculum vulgare, Sambucus nigra and Cassia angustifolia, in a randomized crossover placebo-controlled clinical trial in patients with chronic constipation.

Completed clinical study compared the treatment effects of rabeprazole and lansoprazole depending on the genetic constitution of a enzyme in the liver in treating reflux esophagitis and the cure rate on endoscopy after treatment with rabeprazole 20 mg or lansoprazole 30 mg once daily for 4 to 8 weeks.

Completed study assessed the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.

Chinese Uversity of Hong Kong study comparing the effect of Famotidine plus a COX-2 inhibitor (celecoxib) with Famotidine plus dologesics in ulcer healing in arthritis patients."